The safety profile of drotrecogin alfa (activated)
Open Access
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Critical Care
- Vol. 11 (Suppl 5) , S6
Abstract
Continued safety assessment is essential for any newly approved therapy. Drotrecogin alfa (activated; DrotAA), which is approved for use in severe sepsis, has undergone clinical trials with corresponding safety analyses since 1995. However, the only comprehensive review of all trials is that reported in 2003 by Bernard and coworkers. This is an important review that focuses on the safety profile of DrotAA in all published studies (six randomized clinical trials and five national registry studies) and in previously unpublished data. DrotAA treatment is associated with an increased risk for bleeding (which in general is manageable). Nevertheless, the available evidence shows that any adverse effects of DrotAA are outweighed by its benefits in patients with severe sepsis who are at high risk for death. So far, more than 9,000 patients have been enrolled in clinical trials involving DrotAA, providing a valuable safety database. It is of note that although DrotAA does increase the risk of bleeding, this has not been associated with an overall increase in the rate of all severe adverse events.Keywords
This publication has 29 references indexed in Scilit:
- Second Course of Recombinant Human Activated Protein C Delivered to a Severely Septic Patient After Recent SurgeryJournal of Trauma: Injury, Infection & Critical Care, 2008
- The Neuropathology of Septic ShockBrain Pathology, 2004
- Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe SepsisJAMA, 2003
- Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptorBiochemical Journal, 2003
- Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsisCritical Care, 2003
- Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identificationCritical Care, 2003
- Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsisCritical Care Medicine, 2001
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- The Anticoagulant and Anti-inflammatory Roles of the Protein C Anticoagulant PathwayJournal of Autoimmunity, 2000
- HUMAN PROTEIN C: INACTIVATION OF FACTORS V AND VIII IN PLASMA BY THE ACTIVATED MOLECULE*Annals of the New York Academy of Sciences, 1981